Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Are Recommendations for HTA of Gene Therapies Being Achieved?
11 September 2023
In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.
Around The World in HTAs: Egypt – The Road Ahead
31 July 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Dalia Dawoud, Pillar Pinilla-Dominguez, Caroline Bregman, and Hania El Banhawi take us to Egypt.
The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
18 July 2023
The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS and wider society. The foreword has been provided by Angela Gibbons, patient and HS advocate.
This project has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians.
Around The World in HTAs: India – Let All Be Healthy
29 June 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Shalu Jain and Gayathri Kumar take us to India.
Around The World in HTAs: The Netherlands – 5 Routes for New Tech
24 May 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Iris Boot, Bert Vriijhoef and Lotte Steuten take us to the Netherlands.
Setting the Right Discount Rate for HTA in the Slovak Republic
21 May 2023
Health interventions such as new medicines produce costs and health-related effects not only in the year they are introduced but in all future years until they…
Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
15 May 2023
In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.
Around The World in HTAs: Italy – What’s Next?
20 April 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Claudio Jommi, Università del Piemonte Orientale Novara, and Martina Garau, OHE, take us to Italy.